Drug intelligence / Profile preview

FS013

Development stage: Preclinical
Lead developer: Foreseen Biotechnology
Administration: Intravenous

Overview

FS013 is a preclinical-stage therapeutic candidate being developed by Foreseen Biotechnology for the treatment of solid tumors. The drug was identified using the company's proprietary AI-driven translational proteomics platform, which integrates high-throughput proteomics and clinical data to identify novel tumor-associated targets. While specific details regarding its molecular target and modality have not been publicly disclosed, the program is part of a pipeline focused on precision oncology, including antibody-drug conjugates (ADCs) and targeted biologics. As of 2024, FS013 remains in the early stages of development, representing Foreseen's strategy of leveraging AI to address unmet needs in cancer therapy.

Other names: FS013FS-013FS 013

Beyond the preview

Go deeper on FS013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FS013.

Explore the full profile